Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The optimal level of counseling and frequency of attendance for medication distribution has not been established for the primary care, office-based buprenorphine-naloxone treatment of opioid dependence. METHODS: We conducted a 24-week randomized, controlled clinical trial with 166 patients assigned to one of three treatments: standard medical management and either once-weekly or thrice-weekly medication dispensing or enhanced medical management and thrice-weekly medication dispensing. Standard medical management was brief, manual-guided, medically focused counseling; enhanced management was similar, but each session was extended. The primary outcomes were the self-reported frequency of illicit opioid use, the percentage of opioid-negative urine specimens, and the maximum number of consecutive weeks of abstinence from illicit opioids. RESULTS: The three treatments had similar efficacies with respect to the mean percentage of opioid-negative urine specimens (standard medical management and once-weekly medication dispensing, 44 percent; standard medical management and thrice-weekly medication dispensing, 40 percent; and enhanced medical management and thrice-weekly medication dispensing, 40 percent; P=0.82) and the maximum number of consecutive weeks during which patients were abstinent from illicit opioids. All three treatments were associated with significant reductions from baseline in the frequency of illicit opioid use, but there were no significant differences among the treatments. The proportion of patients remaining in the study at 24 weeks did not differ significantly among the patients receiving standard medical management and once-weekly medication dispensing (48 percent) or thrice-weekly medication dispensing (43 percent) or enhanced medical management and thrice-weekly medication dispensing (39 percent) (P=0.64). Adherence to buprenorphine-naloxone treatment varied; increased adherence was associated with improved treatment outcomes. CONCLUSIONS: Among patients receiving buprenorphine-naloxone in primary care for opioid dependence, the efficacy of brief weekly counseling and once-weekly medication dispensing did not differ significantly from that of extended weekly counseling and thrice-weekly dispensing. Strategies to improve buprenorphine-naloxone adherence are needed. (ClinicalTrials.gov number, NCT00023283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whereas treatment outcomes did not vary significantly by treatment condition,5 patient satisfaction did (F[2, 139] = 3.16, P = .03).”
From Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment (2007) · cites this paper as [5]
In the citing paper
“This paucity of research is particularly noteworthy given the increasing availability and demonstrated efficacy of office-based buprenorphine/naloxone treatment.5–7”
From Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment (2007) · cites this paper as [5]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Effects of Psychosocial Services in Substance Abuse Treatment
McLellan, A. T. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500150065028 · Cited by 869
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577
Crits-Christoph, P. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.493 · Cited by 496
Ensuring balanced distribution of prognostic factors in treatment outcome research.
Stout, R. L., Wirtz, P. W., Carbonari, J. P., & Del Boca, F. K. (1994) · Journal of Studies on Alcohol, Supplement · doi:10.15288/jsas.1994.s12.70 · Cited by 461
Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., Banys, P., & Hall, S. M. (2000) · JAMA · doi:10.1001/jama.283.10.1303 · Cited by 415
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
Carroll, K. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00049-6 · Cited by 386
Research works printed but not linked: 1
- Amato L, 2004, Cochrane Database Syst Rev, 4, CD005031
Cited by
Items 201–300 of 351
Reichert, J., Martins, K. F., Taylor, B. G., & del Pozo, B. (2023) · Journal of Drug Issues · doi:10.1177/00220426231212567 · Cited by 15
“In addition, the medication produces a “ ceiling effect, ” so increasing the doses does not increase its effects, thereby reducing overdose risk (Fiellin et al., 2006; Helm et al., 2008; Mattick et al., 2014).”
Tervonen, H. E., Pentikäinen, H., & Tacke, U. (2013) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2013.01.003 · Cited by 15
“Retention in treatment is similar (Fiellin et al., 2006; Bell et al., 2007; Moore et al., 2012) or even improved (Holland et al.”
BackgroundResultAshford, R. D., Brown, A. M., McDaniel, J. M., Neasbitt, J., Sobora, C., Riley, R., Weinstein, L., Laxton, A. M., Kunzelman, J., Kampman, K. M., et al. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.106031 · Cited by 15
“OBOT models of care typically include induction, stabilization, and on-going pharmacotherapeutic maintenance treatment, with some, but not all, OBOTs offering concurrent psychosocial supports (Fiellin et al., 2006).”
BackgroundSeval, N., Frank, C. A., Litwin, A. H., Roth, P., Schade, M. A., Pavlicová, M., LEVIN, F. R., Brady, K. T., Nunes, E. V., & Springer, S. A. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106394 · Cited by 15
Substance Use in Patients with Sexually Transmitted Infections: Results from a National U.S. Survey
Tetrault, J. M., Fiellin, D. A., Niccolai, L. M., & Sullivan, L. E. (2010) · American Journal on Addictions · doi:10.1111/j.1521-0391.2010.00087.x · Cited by 14
Self-citationAbraham, A. J., Andrews, C. M., Grogan, C. M., Pollack, H. A., D’Aunno, T. A., Humphreys, K. N., & Friedmann, P. D. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201700196 · Cited by 17
Group Medication Management for Buprenorphine/Naloxone in Opioid-Dependent Veterans
Berger, R., Pulido, C., Lacro, J. P., Groban, S. E., & Robinson, S. K. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000071 · Cited by 14
“Many buprenorphine/naloxone studies (O’Conner et al., 1998; Fudala et al., 2003; Fiellin et al., 2006; Bell et al., 2007; Moore et al., 2007; Weiss et al., 2011) have only examined shortterm outcomes (ie, 3 months or less), although Kakko et al.”
BackgroundAdvances in the treatment of opioid use disorders
WOODY, G. E. (2017) · F1000Research · doi:10.12688/f1000research.10184.1 · Cited by 14
Psychosocial Interventions in Office-Based Opioid Treatment: A Systematic Review
Zerden, L. D. S., Guan, T., Lombardi, B. M., Sharma, A., & Garcia-Rico, Y. (2020) · Journal of the Society for Social Work and Research · doi:10.1086/708369 · Cited by 16
“Most of Office-Based Opioid Treatment 121 the articles (n5 18) reported outcomes based on two ormore outcome domains, and four articles reported on all three outcome domains (Fiellin et al., 2002, 2006, 2008; Moore et al., 2012).”
BackgroundTreating Opioid Use Disorder in General Medical Settings
(2021) · Springer eBooks · doi:10.1007/978-3-030-80818-1 · Cited by 15
Is daily supervised buprenorphine-naloxone dosing necessary?
Kleinman, R. A., Nielsen, S., & Weiss, R. D. (2022) · BMJ · doi:10.1136/bmj-2022-071467 · Cited by 13
Characteristics and experiences of buprenorphine-naloxone use among polysubstance users
Walker, R., Logan, T., Chipley, Q. T., & Miller, J. (2018) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1461876 · Cited by 14
Tanner, G., Bordon, N., Conroy, S., & Best, D. W. (2010) · Journal of Substance Use · doi:10.3109/14659891.2010.526480 · Cited by 12
Brooks, A. C., Chambers, J. E., Lauby, J. L., Byrne, E., Carpenedo, C. M., Benishek, L. A., Medvin, R., Metzger, D. S., & Kirby, K. C. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.08.005 · Cited by 16
“, 2013), substance use disorders (Fiellin et al., 2006; Oslin et al., 2006) as well as disorders that often co-occur with substance use disorders (SUDs) such as depression (Archer et al.”
BackgroundMedication-assisted treatment of opiate dependence is gaining favor
Jerry, J. M., & Collins, G. B. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.12181 · Cited by 11
Baldassarri, S. R., Lee, I., Latham, S. R., & D’Onofrio, G. (2018) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110518782925 · Cited by 12
Physician Training is Never a Failure
Gordon, A. J., Liberto, J. C., Granda, S. E., Salmon‐Cox, S., Andrée, T., & McNicholas, L. F. (2009) · American Journal on Addictions · doi:10.1080/10550490902931373 · Cited by 11
Colocating buprenorphine with methadone maintenance and outpatient chemical dependency services
Whitley, S. D., Kunins, H. V., Arnsten, J. H., & Gourevitch, M. N. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.11.003 · Cited by 11
“Intensive counseling may not be indicated for all buprenorphine patients, however (Fiellin et al., 2006).”
BackgroundUchtenhagen, A., Stevens, A., Berto, D., Frick, U., Hunt, N., Kerschl, V., McSweeney, T., Puppo, I., Santamaria, A., Schaaf, S., et al. (2008) · BIROn (Birkbeck, University of London) · doi:10.5167/uzh-15933 · Cited by 13
Advances in the Treatment of Opioid Dependence: Continued Progress and Ongoing Challenges
O’Connor, P. G. (2010) · JAMA · doi:10.1001/jama.2010.1496 · Cited by 14
Self-citationHill, D. R. B., Conroy, S., Afzal, A., Lang, D. L., Steele, S., & Campbell, D. (2014) · Journal of Substance Use · doi:10.3109/14659891.2014.894589 · Cited by 10
“Concurrent counselling and support services are important components of an individual’s recovery process and can significantly improve treatment outcomes by focusing on behaviour modification, motivation, coping skills, interpersonal relationships and social reintegration (Fiellin et al., 2006).”
BackgroundMedication for the Treatment of Opioid Use Disorder
Renner, J. A., & Crawford, M. B. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-16257-3_5 · Cited by 12
Improving Temporal Efficiency of Outpatient Buprenorphine Induction
Gunderson, E. W., LEVIN, F. R., Rombone, M. M., Vosburg, S. K., & Kleber, H. D. (2011) · American Journal on Addictions · doi:10.1111/j.1521-0391.2011.00153.x · Cited by 12
“By delaying treatment initiation, spontaneous withdrawal increased and there was no difference between COWS scores immediately preceding buprenorphine initiation: 10 (3) vs.”
BackgroundInfluentialMontesano, F., Zaccone, D., Battaglia, E., Genco, F., & Mellace, V. (2010) · Clinical Drug Investigation · doi:10.2165/11536040-000000000-00000 · Cited by 13
“In trials using buprenorphine/ naloxone, patients appeared to prefer treatment schedules that required less frequent visits to an office or clinic for medication dispensing.([23-25]) Furthermore, in Italy, buprenorphine/naloxone can be dispensed using a schedule of up to 30 days,([26]) which offers advantages for pati…”
MethodIntegration of substance use treatment and medical care: A special issue of JSAT
Walley, A. Y., Tetrault, J. M., & Friedmann, P. D. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2012.09.002 · Cited by 12
Novel Therapeutic and Program-Based Approaches to Opioid Use Disorders
Liu, P., Korthuis, P. T., & Buchheit, B. M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033924 · Cited by 11
McHugh, R. K., Hilton, B. T., Chase, A. R., Griffin, M. L., & Weiss, R. D. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109084 · Cited by 14
Andraka‐Christou, B., Golan, O. K., Williams, M., Buksbaum, S., Gordon, A. J., & Stein, B. D. (2024) · Substance Use & Addiction Journal · doi:10.1177/29767342231223721 · Cited by 10
2013 Update in addiction medicine for the generalist
Gordon, A. J., Bertholet, N., McNeely, J., Starrels, J. L., Tetrault, J. M., & Walley, A. Y. (2013) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-8-18 · Cited by 11
Bernardy, N. C., Hamblen, J. L., Friedman, M. J., & Kivlahan, D. R. (2011) · Journal of Dual Diagnosis · doi:10.1080/15504263.2011.620446 · Cited by 10
“Buprenorphine is a partial opiate agonist which can assist with effective medical withdrawal from opiates or work as a partial agonist maintenance medication (Fiellin et al., 2006).”
BackgroundBlasco, J., Martínez-Raga, J., Carrasco, E., & Didia-Attas, J. (2008) · Adicciones · doi:10.20882/adicciones.259 · Cited by 26
Psychosocial Approaches in the Treatment of Opioid Use Disorders
Bergman, B. G., Fallah‐Sohy, N., Hoffman, L. A., & Kelly, J. F. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-16257-3_6 · Cited by 11
Topmiller, M., Mallow, P. J., Vissman, A. T., & Grandmont, J. (2018) · Journal of health economics and outcomes research · doi:10.36469/9787 · Cited by 12
Medicine, with a Focus on Physicians: Addressing Substance use in the 21st Century
Levy, S., Seale, J. P., & Alford, D. P. (2019) · Substance Abuse · doi:10.1080/08897077.2019.1691130 · Cited by 11
Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings
Hooker, S. A., Starkey, C., Bart, G. B., Rossom, R. C., Kane, S. M., & Olson, A. W. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02609-9 · Cited by 9
“In contrast, in controlled clinical trials, adherence by self-report and/ or electronic monitoring of prescription bottle caps is approximately 70%, with missed dosing being a common reason for non-adherence [22, 23].”
BackgroundResultPerez-Correa, A., Abbas, B. T., Riback, L. R., Ghiroli, M. M., Norton, B. L., Murphy, S. M., Jakubowski, A. U., Hayes, B. T., Cunningham, C. O., & Fox, A. D. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106674 · Cited by 8
Moving HIV Pre-Exposure Prophylaxis Into Clinical Settings
Edelman, E. J., & Fiellin, D. A. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2012.09.035 · Cited by 9
Self-citationBanta‐Green, C. J., Hansen, R. N., Ossiander, E. M., Wasserman, C. R., & Merrill, J. O. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108446 · Cited by 8
Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder
Bhatraju, E. P., Radick, A. C., Leroux, B. G., Kim, T. W., Samet, J. H., & Tsui, J. I. (2023) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2023.2220876 · Cited by 12
“2006 (28) measured adherence at the patient level and found an association with non-prescribed opioid use.”
BackgroundNeurorobiology and Evidence-Based Biological Treatments for Substance Abuse Disorders
Ivanov, I., Schuiz, K. P., Palmero, R. C., & Newcorn, J. H. (2006) · CNS Spectrums · doi:10.1017/s1092852900015017 · Cited by 11
Guideline for Physicians Working in California Opioid Treatment Programs
Stephenson, D. K. (2005) · Cited by 8
Rawson, R. A., Gonzales, R. E., Greenwell, L., & Chalk, M. (2012) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2012.718653 · Cited by 11
“Prior research supports the comparison of different approaches, including these two, when constructing an ITT data set (Pettinati et al. 2008; Woody et al. 2008; Fiellin et al. 2006; Leon et al. 2006; Fischer et al. 1999).”
MethodEmpirically contrasting urine drug screening‐based opioid use disorder treatment outcome definitions
Brandt, L., Odom, G., Hu, M., Castro, C., Balise, R. R., & the CTN‐0094 Team (2024) · Addiction · doi:10.1111/add.16494 · Cited by 7
DeMaria, P. A., Sterling, R. C., Risler, R., & Frank, J. (2010) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3181cf2050 · Cited by 7
“Although adding psychosocial treatment to medication is recommended (Center for Substance Abuse Treatment, 2004), Fiellin et al. (2006) were not able to demonstrate that additional counseling led to improved treatment outcome in an office-based buprenorphine treatment program.”
BackgroundGalanter, M. S., Femino, J., Hunter, B. D., & Hauser, M. (2020) · American Journal on Addictions · doi:10.1111/ajad.13001 · Cited by 7
Berry, A. R. W., Finlayson, T. L., Mellis, L. M., & Urada, L. A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111072 · Cited by 5
“Some studies of office-based buprenorphine treatment showed no relationship to engagement in counseling [34].”
BackgroundDifferences in buprenorphine treatment quality across physician provider specialties
Levin, J. S., Landis, R. K., Sorbero, M., Dick, A. W., Saloner, B. K., & Stein, B. D. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109510 · Cited by 10
Paola, A. D., Taweh, N., Biondi, B. E., Forray, A., Frank, C. A., Shaw, A. C., & Springer, S. A. (2022) · American Journal on Addictions · doi:10.1111/ajad.13304 · Cited by 8
Peter, S. C., Murphy, J. G., Witkiewitz, K. A., Hand, S. B., Thomas, F., Johnson, K., Cowan, R. L., Harris, M., & Derefinko, K. J. (2023) · Trials · doi:10.1186/s13063-023-07102-9 · Cited by 11
“Unfortunately, MOUD adherence is very low [5, 6].”
ResultBuprenorphine for Prescription Opioid Addiction in a Patient With Depression and Alcohol Dependence
Fishman, M. J., Wu, L.-T. T., & WOODY, G. E. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10060879 · Cited by 8
The Availability of Ancillary Counseling in the Practices of Physicians Prescribing Buprenorphine
Barry, D. T., Fazzino, T. L., Necrason, E., Ginn, J., Fiellin, L. E., Fiellin, D. A., & Moore, B. A. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000247 · Cited by 7
“…disorder, physician (J Addict Med 2016;10: 352–356) B uprenorphine is effective in treating opioid use disorder(Ling et al., 1998; Fudala et al., 2003; Fiellin et al., 2006; Schottenfeld et al., 2008) and is considered an essential medication for this indication (World Health Organization, 2013).”
BackgroundSelf-citationThe Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review
Carroll, K. M., & Weiss, R. D. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17206 · Cited by 10
Clinical Experience with Fortnightly Buprenorphine/Naloxone versus Buprenorphine in Italy
Amato, P. (2010) · Clinical Drug Investigation · doi:10.2165/11536060-000000000-00000 · Cited by 7
“The successful application of buprenorphine/ naloxone in an outpatient setting in the current study adds to the existing body of literature documenting the use of buprenorphine and buprenorphine/naloxone outside an addiction clinic.([9,11,12,18-25]) In addition, the use of officebased sublingual buprenorphine therapy…”
MethodLowenstein, M., Popova, E., Jalloh, A., Mazzella, S., Botcheos, D., Bertocchi, J., Westfahl, S., Garcia, K. P., Truchil, R., & Chertok, J. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209429 · Cited by 6
Pharmacotherapy of Opioid Use Disorder—Update and Current Challenges
Racha, S., Buresh, M., & Fingerhood, M. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.04.001 · Cited by 7
Multimodal Acute Pain Management in the Parturient with Opioid Use Disorder: A Review
Koltenyuk, V., Mrad, I., Choe, I., Ayoub, M. I., Kumaraswami, S., & Xu, J. L. (2024) · Journal of Pain Research · doi:10.2147/jpr.s434010 · Cited by 9
“66 One study found that patients using buprenorphine were adherent 71% of the time.”
BackgroundHIV Testing and Sexual Risk Reduction Counseling in Office-Based Buprenorphine/Naloxone Treatment
Edelman, E. J., Moore, B. A., Caffrey, S., Sikkema, K. J., Jones, E. S., Schottenfeld, R. S., Fiellin, D. A., & Fiellin, L. E. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3182a3b603 · Cited by 6
“In conjunction with the buprenorphine/naloxone treatment, all patients received physician management and a brief (15 minutes/session), manual-guided counseling session to promote abstinence from illicit substances, occurring twice monthly for the duration of the study (Fiellin et al., 2006; Sullivan et al., 2006; Tetr…”
BackgroundMethodResultInfluentialSelf-citationAntagonist—agonist combinations as therapies for heroin addiction: back to the future?
Nutt, D. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109356129 · Cited by 6
“Trials of office treatments were then instigated and proved the combination effective both within (Fiellin et al., 2006; Fudala et al., 2003; Gorlick et al., 2008) and outside (Clark, 2003; Helm et al.”
BackgroundMethodHealth Insurance Enrollment and Availability of Medications for Substance Use Disorders
Abraham, A. J., Rieckmann, T. R., Andrews, C. M., & Jayawardhana, J. (2016) · Psychiatric Services · doi:10.1176/appi.ps.201500470 · Cited by 8
Commentary on Burns et al . (2015): Retention in buprenorphine treatment
Saxon, A. J. (2015) · Addiction · doi:10.1111/add.12865 · Cited by 6
Reif, S., Stewart, M. T., Daily, S. M., Brolin, M. F., Lee, M. T., Panas, L., Ritter, G. A., Shields, M. C., Mazel, S. B., & Wicks, J. J. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209544 · Cited by 5
Capturing the Full Range of Buprenorphine Treatment Response
Bailey, A. J., Votaw, V. R., Weiss, R. D., & McHugh, R. K. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.3836 · Cited by 5
Eren, K., Schuster, J., Herschell, A. D., Loveland, D., Neimark, G. B., Mihalyo, M. J., Hurford, M. O., Houck, P. R., & Ryan, N. D. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000914 · Cited by 6
Expanding Buprenorphine Use in Primary Care: Changing the Culture
Leiser, A., & Robles, M. (2022) · The Permanente Journal · doi:10.7812/tpp/21.203 · Cited by 6
Heroin Use, HIV-Risk, and Criminal Behavior in Baltimore: Findings from Clinical Research
Schwartz, R. P., Kelly, S. M., Gryczynski, J., Mitchell, S. G., O’Grady, K. E., & Jaffe, J. H. (2015) · Journal of Addictive Diseases · doi:10.1080/10550887.2015.1059222 · Cited by 5
Treatment of Opioid Dependence
Saxon, A. J. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131.ch005 · Cited by 5
McHugh, R. K., Bailey, A. J., McConaghy, B. A., Weiss, R. D., Fiellin, D. A., Hillhouse, M. P., Moore, B. A., & Fitzmaurice, G. M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.28529 · Cited by 7
Self-citationCognitive behavioral therapy for anxiety and opioid use disorder: Development and pilot testing
McHugh, R. K., Fitzmaurice, G. M., Votaw, V. R., Geyer, R. B., Ragnini, K., Greenfield, S. F., & Weiss, R. D. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209296 · Cited by 9
Helm, A. F., Shaffer, P. M., Gonzalez, G. M., Li, W., Olmstead, T. A., Berlowitz, D., Epstein, E. E., & Smelson, D. A. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107668 · Cited by 4
“Narcotics helped, I thought.” Recurrent Traumatization and Recovery from Drug Dependence
Kueppenbender, K. D., Herman, J. L., Khantzian, E. J., & Albanese, M. A. (2008) · Harvard Review of Psychiatry · doi:10.1080/10673220802432418 · Cited by 5
Clinical Case Conference: Unobserved “Home” Induction Onto Buprenorphine
Lee, J. D., McNeely, J., Grossman, E., Vocci, F. J., & Fiellin, D. A. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000060 · Cited by 4
“Induction with buprenorphine/naloxone products has been reported to be feasible and safe for many years (Fiellin et al., 2006; Moore et al., 2007; Ling et al., 2010).”
BackgroundInfluentialSelf-citationBridging Social Capital: A Clinical Sociology Approach to Substance Use Intervention
Boeri, M. W. (2020) · Clinical sociology · doi:10.1007/978-3-030-54584-0_9 · Cited by 6
Telehealth Approaches to Improve Opioid Use Care in Pregnancy
Harper, L. M. (2021) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000607 · Cited by 4
2012 Update in addiction medicine for the generalist
For the US Society of General Internal Medicine’s Substance Abuse Interest Group, Rastegar, D. A., Kunins, H. V., Tetrault, J. M., Walley, A. Y., & Gordon, A. J. (2013) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-8-6 · Cited by 9
Correlates of death during outpatient treatment for opioid use disorder: A national study
Goldman, J. A., Samuels, E. A., Rich, J. D., & Marshall, B. D. L. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.01.003 · Cited by 6
Heroin and the Opium Poppy Plant ( Papaver somniferum L.)
Barceloux, D. G. (2012) · Wiley eBooks · doi:10.1002/9781118105955.ch31 · Cited by 5
Counseling plus Buprenorphine–Naloxone for Opioid Dependence
Gorelick, D. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmc062301 · Cited by 4
Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study
Lowenstein, M., Davis, M. H., Aronowitz, S. V., Seeburger, E. F., & Grande, D. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112586 · Cited by 3
Shulman, M., Provost, S. E., Ohrtman, K., Novo, P., Meyers-Ohki, S. E., Veldhuisen, P. C. V., Oden, N. L., Otterstatter, M. C., Bailey, G. L., Liu, D., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107543 · Cited by 3
Song, G., Tian, C., Wu, L., Liu, M., & Lu, H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1092199 · Cited by 4
“Clinicians should identify older adults at high risk for ED visits and hospitalizations and encourage them to use evidence-based interventions, such as non-pharmacological pain management interventions (51), behavioral therapies (52), and counseling (53, 54) to treat”
BackgroundMiller‐Rosales, C., Busch, S. H., Meara, E. R., King, A. C., D’Aunno, T. A., & Colla, C. H. (2023) · Medical Care Research and Review · doi:10.1177/10775587231162681 · Cited by 3
“Effective treatment for opioid use disorder (OUD) is available through the prescription of medications for OUD (MOUD), including buprenorphine, methadone, and naltrexone (Fiellin et al., 2006; Haffajee et al., 2019; Madras et al., 2020).”
BackgroundMcHugh, R. K., Bailey, A. J., Weiss, R. D., & Fitzmaurice, G. M. (2024) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2024.100226 · Cited by 6
“This is evident in the 4 trials we selected, with some studies defining the primary outcome as opioid use over the entire course of the trial (Fiellin et al., 2006) and others defining outcome as treatment response late in the treatment episode (e.g., last 4 weeks of treatment; Weiss et al., 2011).”
BackgroundMethodInfluentialBuprenorphine for opioid addiction
Ling, W. W., Mooney, L. J., & Torrington, M. (2013) · Neuropsychiatry · doi:10.2217/npy.13.47 · Cited by 5
Drug and alcohol addiction: new pharmacotherapies
Luty, J. S. (2015) · BJPsych Advances · doi:10.1192/apt.bp.114.013367 · Cited by 4
“Suboxone is a proprietary combination of the opioid partial agonist buprenorphine and the opioid antagonist naloxone a (Fiellin 2006).”
Dutta, A. S. (2009) · Wiley eBooks · doi:10.1002/9781444317800.ch1 · Cited by 3
Substance misuse problems during pregnancy with special emphasis on buprenorphine
Kahila, H. K. (2011) · Helda - University of Helsinki Institutional Repository · Cited by 13
Pippin, M. (2026) · Cureus · doi:10.7759/cureus.103848 · Cited by 2
“A 2006 randomized controlled trial by Fiellin et al. compared pharmacologic-focused primary care opioid use disorder management with varying levels of additional supportive counseling interventions and found no difference in outcomes between the groups [64].”
Reflections on Person-Centered Group Therapy from Clients in Opioid Treatment
Ripley, D., & Welfare, L. E. (2021) · The Journal for Specialists in Group Work · doi:10.1080/01933922.2021.1950879 · Cited by 3
“A Viable Option Results provide a richer understanding of the client experience of group in MAT, which is a helpful supplement to the quantitative literature on counseling in MAT with buprenorphine (Fiellin et al., 2013, 2006; Ling et al., 2013; Weiss & Rao, 2017; Moore et al., 2012, 2016).”
BackgroundMethodYue, J.-L., Wang, R., Chen, S., Lin, X., Fang, Q., Guo, X.-J., Sun, Y., Yuan, K., Bao, Y., Shi, J., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03474-5 · Cited by 4
“To ensure balanced distribution of critical demographic and clinical variables across the three intervention groups, we implemented an urn randomization procedure with strati fi cation for educational attainment, addiction severity, and gender [29].”
Trastornos por consumo de sustancias y fármacos
Dolengevich-Segal, H., Salgado, B. R., Mínguez, F. M., & Quintero, J. (2015) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2015.09.003 · Cited by 7
(2021) · International Journal of Addiction Research and Therapy · doi:10.28933/ijart-2021-06-1005 · Cited by 2
Tetrault, J. M., Tate, J. P., Edelman, E. J., Gordon, A. J., Re, V. L., Lim, J. K., Rimland, D., Goulet, J. L., Crystal, S., Gaither, J. R., et al. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.06.002 · Cited by 2
Self-citationImproving maintenance treatment of opiate addiction: Clinical aspects
Simojoki, K. (2013) · Helda - University of Helsinki Institutional Repository · Cited by 8
Dermatis, H., & Galanter, M. S. (2007) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.5.2.foc141 · Cited by 2
Buprenorphine: A more accessible treatment for opioid dependence
Flassing, J. (2010) · JAAPA · doi:10.1097/01720610-201009000-00008 · Cited by 2
Psychosocial Treatment Methods
Peirce, J. M., Antoine, D. G., Hammond, A. S., & KIDORF, M. S. (2023) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197618431.013.25 · Cited by 2
Nnanna, T. B. (2024) · International Journal of Pharmacy and Chemistry · doi:10.11648/j.ijpc.20241004.11 · Cited by 1
“Typically, psychosocial therapy is added to substitution therapeutic interventions, which has proven to expand the proportion of respondents who abstain at later investigations [91, 92].”
Masyukova, M., Hayes, B. T., López‐Castro, T., & Fox, A. D. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00540-7 · Cited by 2
“With two decades of clinical experience and numerous clinical trials demonstrating efficacy, BUP treatment in primary care will continue to be a first-line OUD treat-ment; however, there is room for practice improvement [5, 39].”
Szerman, N., Bobes, J., & Cobos, J. P. D. L. (2009) · Trastornos Adictivos · doi:10.1016/s1575-0973(09)73465-8 · Cited by 1
Buprenorphine Implants and Opioid Dependence—Reply
O’Connor, P. G. (2011) · JAMA · doi:10.1001/jama.2010.1991 · Cited by 1
Self-citation
Metadata
- Authors
- Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S.
- Affiliations
- Yale University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-07-27
- Volume
- 355
- Issue
- 4
- Pages
- 365-374
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1964032526
- Cited by
- 351
- References
- 30
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 17 · 2023: 14 · 2022: 13 · 2021: 28 · 2020: 18 · 2019: 24 · 2018: 22 · 2017: 19 · 2016: 11 · 2015: 19 · 2014: 18 · 2013: 18 · 2012: 15
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (K24DA000445, K23 DA15144, R01DA009803, K12 DA00167, K23DA015144, K12DA000167)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, buprenorphine/naloxone, medication-assisted treatment, counseling, primary care, medication adherence, opioid abstinence, urine drug testing, treatment retention
- MeSH terms
- Adult, Buprenorphine, Combined Modality Therapy, Counseling, Female, Humans, Male, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.